COVID-19 vaccine made by a Canadian company.Providence Therapeutics of Calgary says 60 subjects will be monitored for 13 months, with the first results expected next month.The group of healthy volunteers aged 18 to 65 have been divided into four groups of 15.
Three of the groups will get three different dose levels, while a fourth group gets a placebo. Canadian company urges human trials after COVID-19 vaccine in mice blocked virus Pending regulatory approval, the company’s CEO Brad Sorenson says a larger Phase 2 trial may start in May with seniors, younger subjects and pregnant people.[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]Providence uses messenger RNA technology for a product it calls PTX-COVID19-B. .